Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Abeprazan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abeprazan SCHEMBL29719476 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29443418 | 1.00 | HTR6 (0.39) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385615 | 0.99 | HTR6 (0.40) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201776 | 0.97 | HTR6 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL29201774 | 0.95 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Abeprazan SCHEMBL19385601 | 0.94 | FABP4 (0.38) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18190937 | 0.93 | HTR6 (0.35) | HTR6DRD2MEN1GFERKMT2A | |
| SCHEMBL18196931 | 0.93 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 | |
| Abeprazan SCHEMBL19385619 | 0.93 | HTR6 (0.37) | HTR6DRD2MEN1GFERKMT2A | |
| Hydrochloric Acid SCHEMBL20530226 | 0.92 | HTR6 (0.40) | HTR6DRD2HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756695-A | Novel crystalline forms of highly water-soluble salts of novel 4-methoxypyrrole derivatives | 罗欣药业(上海)有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-117756694-A | High water soluble salt of new 4-methoxy pyrrole derivative and its preparation method | 罗欣药业(上海)有限公司 | 2024-03-26 | — | — | CN | claimed |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | claimed |
| CN-108602771-B | Acid addition salts of compounds | 株式会社大熊制药 | 2021-07-16 | — | — | CN | claimed |
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-05-13 | — | — | US | claimed |
| EP-3433233-B1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE SALT | DAE WOONG PHARMA (KR) | 2020-07-22 | — | — | EP | claimed |
| EP-3433232-B1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAE WOONG PHARMA (KR) | 2020-07-15 | — | — | EP | claimed |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2019-01-31 | — | — | US | claimed |
| EP-3433232-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | Daewoong Pharmaceutical Co., Ltd. (KR) | 2019-01-30 | — | — | EP | claimed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | claimed |
| US-20260048041-A1 | COMPOSITION FOR REMOVING HELICOBACTER PYLORI COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JEIL PHARMACEUTICAL CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| EP-4079293-B1 | LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROLE-3-YL)-N-METHYLMETHANEAMINE | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4079293-B1 | LIQUID PHARMACEUTICAL COMPOSITION OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROLE-3-YL)-N-METHYLMETHANEAMINE | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2026-02-11 | — | — | EP | disclosed |
| EP-4245298-B1 | NOVEL FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2026-01-21 | — | — | EP | disclosed |
| EP-4245298-B1 | NOVEL FORMULATION FOR ORAL ADMINISTRATION, COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2026-01-21 | — | — | EP | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017164575-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3- FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N- METHYLMETHANAMINE | DAEWOONG PHARMACEUTICAL CO.,LTD. (KR) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016175555-A2 | NOVEL 4-METHOXY PYRROLE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139424-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885DRD2 3245/4885MEN1 1926/4885 |
| US-20260048041-A1 | COMPOSITION FOR REMOVING HELICOBACTER PYLORI COMPRISING ZASTAPRAZAN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CEL, PGC, SLC30A5 | HTR6 2372/4885DRD2 4283/4885MEN1 4701/4885 |
| US-20230159454-A1 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | FH, FIS1, SUCNR1 | HTR6 2561/4885DRD2 3245/4885MEN1 1926/4885 |
| US-20190031609-A1 | NOVEL ACID ADDITION SALT OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | PGA5, MIF, JUN | HTR6 2116/4885DRD2 2194/4885MEN1 2900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.